
ALT “Happy” hereditary breast and ovarian cancer week. Here is a data consolidation retro case study about a correlation between “aspirin use and reduced ovarian cancer risk” https://ascopubs.org/doi/abs/10.1200/JCO.21.01900?journalCode=jco&fbclid=IwAR2DNZRun3-Vs8q73JFF4jrcZSinh6M7s-n92GPFPuwJBYwuoihhNsO2C20  Also from ‘18 but newer studies ongoing- “A new ovarian cancer study explores the possibility of a prevention strategy with aspirin OV.25 study targets woman who have the confirmed genetic mutation BRCA1 or BRCA2 https://www.ctg.queensu.ca/cctg_news/new-ovarian-cancer-study-explores-possibility-prevention-strategy-aspirin?fbclid=IwAR06rl9-OV2PQ7kgoExyV1O-7HMIDf3yUb2lXK6uBFXX4BdBiUbzbyfpzig “ I wonder if there’s a link between BRCA genes affecting blood stem cell production, and aspirin being an anti-platelet agent

ALT Panel A: The treatment course of the study patient with small-cell carcinoma of ovary hypercalcemic type (SCCOHT). Panel B: The results of immunohistochemical (IHC) analysis, indicating loss of BRG1 (at left) and BRM1 (at right), findings that are characteristic of SMARCA4-deficient tumors. Panel C: The patient’s tumor response to tazemetostat, according to Response Evaluation Criteria in Solid Tumors (RECIST).


























